Back
Science

GLP-1 Medications: New Treatments, Genetic Factors, and Evolving Market Dynamics

Generated on: Last updated: 43 sources
View source

The Shifting Landscape of GLP-1 Drugs: New Approvals, Genetic Insights, and Market Turmoil

The pharmaceutical and medical landscape surrounding GLP-1 receptor agonists is undergoing significant changes, marked by new drug approvals, expanded indications, research into genetic factors affecting efficacy, and shifting market dynamics related to cost and access.

This report synthesizes recent developments, including new oral medications, evolving pipeline drugs, research on drug mechanisms and side effects, and changes in insurance coverage.

New Drug Approvals and Market Entry

Eli Lilly's Foundayo (Orforglipron)

The U.S. Food and Drug Administration (FDA) approved Foundayo, Eli Lilly's once-daily oral medication for obesity. Foundayo is the second GLP-1 pill for weight loss, following Novo Nordisk's Wegovy pill.

The starting cash price is $149 per month, with higher doses costing up to $299 per month for patients with continuous prescription renewals.

  • Mechanism: Foundayo's active ingredient, orforglipron, is a non-peptide small molecule designed for easier oral absorption. It can be taken at any time without food or water restrictions. This contrasts with the Wegovy pill, which must be taken on an empty stomach with a 30-minute fasting period.
  • Clinical Trial Data: In an 18-month Phase 3 trial, participants receiving the highest dose of Foundayo lost an average of 27.3 pounds (12.4% of body weight), compared to 2.2 pounds (0.9%) in the placebo group. Common side effects included nausea, constipation, and diarrhea.
  • Pricing and Access: Eli Lilly anticipates commercial insurance copays could be as low as $25 per month with a savings card. Medicare coverage is expected to begin in July, with copays around $50 per month. The drug is expected to be available in pharmacies within one to two weeks. The FDA reviewed Foundayo in 50 days under a pilot program for drugs aligned with national health priorities.
  • Competition and Voucher Program: Foundayo's approval occurred under the FDA's commissioner's voucher program. This program has been subject to scrutiny, with some agency insiders alleging political interference. Eli Lilly received a voucher as part of an agreement with the White House to reduce obesity drug prices in specific contexts. Novo Nordisk stated that direct comparative trials between orforglipron and the Wegovy pill have not been conducted.

Novo Nordisk's Higher-Dose Wegovy and Oral Pill

  • Higher-Dose Injectable: The FDA approved a new 7.2-milligram dose of Novo Nordisk's injectable Wegovy (semaglutide), up from the previous highest dose of 2.4 milligrams. The higher dose received accelerated review and was approved 54 days after the request. In a study, the 7.2-mg dose helped participants achieve approximately 19% body weight loss (nearly 47 pounds) over nearly 17 months, compared to about 16% (39 pounds) with the lower dose. Side effects included nausea, vomiting, and constipation in over 70% of users, and unpleasant skin sensations in about 23% of users. The dose is expected to be available in U.S. pharmacies in April.
  • Oral Wegovy Pill: Novo Nordisk launched the oral version of Wegovy, the first FDA-approved oral GLP-1 medication for chronic weight management. The pill, which contains 25 milligrams of semaglutide, is taken daily. Clinical trials showed an average weight loss of 13.6% over 64 weeks. The starting dose has a cash price of $149 per month, with higher doses priced at $299 per month. For insured patients, copays may be as low as $25 per month.

Pipeline and Future Developments

Eli Lilly's Retatrutide

Eli Lilly's investigational drug, retatrutide, successfully completed its initial late-stage trial in patients with Type 2 diabetes.

  • Mechanism of Action: Retatrutide is a "triple G" drug that mimics three hunger-regulating hormones: GLP-1, GIP, and glucagon. This differentiates it from current treatments like Zepbound (mimics GLP-1 and GIP) and Wegovy (mimics only GLP-1).
  • Trial Results: In patients with Type 2 diabetes, the drug lowered hemoglobin A1c by an average of 1.7% to 2% across various doses over 40 weeks. Patients receiving the highest dose lost an average of 16.8% of their body weight (36.6 pounds) at 40 weeks. In a separate study involving individuals with knee osteoarthritis, retatrutide led to an average body weight loss of up to 29% over 68 weeks.
  • Safety Profile: The drug's safety profile was consistent with other injectable diabetes and obesity medications, with gastrointestinal issues as the primary side effects. Low rates of dysesthesia, an unpleasant nerve sensation, were also observed.
  • Future Outlook: Eli Lilly has not yet submitted retatrutide for regulatory approval for either obesity or diabetes. The company anticipates releasing results from seven additional Phase 3 trials by the end of the year.

Efficacy Comparisons and Clinical Context

Head-to-head clinical trials comparing the efficacy of the Wegovy pill and Foundayo have not been conducted. Available data from separate trials shows the following:

  • Novo Nordisk's Wegovy pill: 13.6% average weight loss over 64 weeks.
  • Eli Lilly's Foundayo (orforglipron): 12.4% average weight loss over 72 weeks.
  • Eli Lilly's injectable Zepbound (tirzepatide): Over 20% weight reduction in studies.
  • Novo Nordisk's higher-dose injectable Wegovy (7.2 mg): Approximately 19% weight loss over 17 months.

Dr. Jody Dushay, an endocrinologist at Harvard Medical School, noted that some patients transitioning from injectable to oral Wegovy have reported less weight loss and expressed a cautious outlook on the long-term effectiveness of the pills for significant weight reduction.

"Approximately 10% of the population carries these genetic variants," which are linked to a phenomenon researchers term GLP-1 resistance.

Genetic Factors Influencing Drug Response

PAM Gene Variants and GLP-1 Resistance

A study published in Genome Medicine on March 29 found that specific genetic variants in the PAM (peptidyl-glycine alpha-amidating monooxygenase) gene are associated with reduced effectiveness of GLP-1 receptor agonist medications for blood sugar control.

  • Prevalence: Approximately 10% of the population carries these genetic variants, which are linked to a phenomenon researchers term GLP-1 resistance.
  • Research Findings: In individuals with these variants, levels of the hormone GLP-1 are higher than normal but appear less biologically effective. In clinical trial data involving 1,119 participants with diabetes, individuals with PAM variants responded less effectively to GLP-1 drugs. After six months of treatment, approximately 25% of participants without the variants met recommended HbA1c targets, compared to 11.5% of those with one specific variant (p.S539W) and 18.5% with another (p.D563G).
  • Context: The genetic variants did not affect response to other common diabetes medications like sulfonylureas, metformin, or DPP-4 inhibitors. Two additional trials using longer-acting GLP-1 drugs showed no difference in response between carriers and non-carriers, suggesting longer-lasting formulations may help overcome the resistance. It remains unclear whether these genetic variants influence weight loss outcomes from GLP-1 drugs.

23andMe Study on Obesity Drug Response

A study published in Nature analyzed data from approximately 28,000 users of the 23andMe DNA-testing service who reported using weight-loss drugs. The study found that one specific genetic variant was associated with increased weight loss from GLP-1 medications, while other variants were linked to a higher risk of side effects, such as nausea. Individuals carrying one copy of a variant in the GLP-1 receptor gene experienced an average of 0.76 kilograms more weight loss over approximately eight months of treatment.

Dietary and Lifestyle Recommendations for GLP-1 Users

Nutritionists and medical professionals have outlined principles for a diet while using GLP-1 medications.

  • Core Nutritional Guidelines: A balanced approach includes adequate protein to counteract potential muscle loss, fiber from fruits and vegetables to mitigate slowed digestion and prevent constipation, and ample hydration as GLP-1 drugs can diminish thirst sensation.
  • Challenges: Many individuals initially lose weight without altering eating habits. Skipping meals followed by consuming calorie-dense food can trigger adverse effects like nausea, vomiting, or constipation. Data indicates that approximately half of users discontinue GLP-1 drugs within a year, often leading to rapid weight regain.
  • "GLP-1 Friendly" Labels: While food companies are introducing products marketed as "GLP-1 Friendly," nutritionists advise caution. No regulated or medically defined standard exists for these claims, rendering them primarily marketing terms.
  • Specific Lifestyle Recommendations: Experts recommend consuming 20-30 grams of protein per meal, increasing fiber intake, drinking 8-12 cups of water daily, engaging in 150 minutes of aerobic exercise weekly with 30 minutes of strength training two to three times per week, and ensuring 7-9 hours of sleep per night.

Research on Mechanisms and Side Effects

GLP-1 Drug Benefits Independent of Weight Loss

A study led by Dr. Daniel Drucker at the University of Toronto, published Tuesday, identified a mechanism by which GLP-1 medicines can improve liver health independently of weight loss. Researchers created "weight non-responder" lab mice by eliminating GLP-1 receptors in their brains. In these mice, semaglutide still produced substantial benefits for liver health, specifically improving markers of metabolic dysfunction-associated steatohepatitis (MASH). The study identified a rare population of blood vessel cells in the liver that, when stimulated by GLP-1, initiates a process to reduce inflammation. Clinical trials suggest 10-15% of people taking GLP-1 drugs for weight loss are "non-responders" regarding substantial weight reduction. In August, the FDA approved Wegovy for treating MASH.

Reported Side Effects and Risks

A review of studies and medical reports indicates GLP-1 drugs may provide benefits for heart disease, liver disease, and other conditions, while also posing risks.

  • Heart Disease: A 2023 study of over 17,000 patients found semaglutide reduced the risk of major cardiovascular events by about 20% in overweight or obese adults with cardiovascular disease.
  • Addiction and Mental Health: A study of over 2 million people found reduced risks of addiction to alcohol, cannabis, stimulants, and opioids among GLP-1 users.
  • Other Reported Side Effects: These include hair loss, muscle loss, droopy skin, vision problems, dental issues, and gallbladder disease.

Potential Impact on Sexual Health

A review published in Obesity Pillars in March 2026 proposed that GLP-1 medications may influence sexual desire by affecting brain chemistry. Dr. James Simon, an ob-gyn and reproductive endocrinologist involved in the study, stated that the brain regions controlling appetite are also involved in other reward-seeking behaviors, which could explain anecdotal reports of decreased interest in sex among some users. Scientific research into this relationship is currently limited.

Colorectal Cancer Symptoms Masked by GLP-1 Side Effects

Medical professionals have reported cases where common gastrointestinal side effects of GLP-1 drugs, such as constipation and abdominal discomfort, have masked early signs of colorectal cancer, leading to delayed diagnoses. Two women in the US reported that their colorectal cancer symptoms were initially attributed to their GLP-1 medications. Dr. David Greenwald from Mount Sinai Hospital noted that GLP-1s do not cause rectal bleeding or stool narrowing, which should be evaluated. Colorectal cancer screening is recommended starting at age 45 for average-risk individuals.

Insurance Coverage and Cost Dynamics

State and City Medicaid and Public Employee Coverage

Several U.S. state Medicaid programs and city health plans have recently restricted or eliminated coverage for GLP-1 drugs prescribed for weight loss, citing significant increases in public spending.

National spending on GLP-1 drugs increased from $13.7 billion in 2018 to $71.7 billion in 2023.

  • Policy Changes: As of January 2026, California, New Hampshire, Pennsylvania, and South Carolina ended Medicaid coverage of GLP-1 drugs for weight loss. Michigan restricted coverage to individuals classified as morbidly obese (BMI above 40). New York City's health insurer stopped covering the drugs for city employees in 2025, and Boston is considering similar limits.
  • Spending Data: National spending on GLP-1 drugs increased from $13.7 billion in 2018 to $71.7 billion in 2023. In Pennsylvania, Medicaid spending on GLP-1 drugs was $1.3 billion in 2025, double the amount from the previous year.
  • Legislative Proposals: Pennsylvania State Representative Arvind Venkat has introduced legislation to create a subscription-based "value-based arrangement" with drug manufacturers, similar to a model Louisiana used for hepatitis C drugs.
  • Future Cost Outlook: Dr. Matthew Klebanoff of the Perelman School of Medicine suggested drug costs may decrease as market competition increases, drawing a parallel to the price trajectory of hepatitis C treatments.

Payer Formulary Changes

CVS Caremark removed Eli Lilly's Zepbound from its formulary in July 2025, requiring some patients to switch to Novo Nordisk's Wegovy. Research by GoodRx indicates that 12 million people lost coverage for Zepbound and 12 million lost coverage for Wegovy from 2025 to 2026. 88% of patients with GLP-1 drug coverage face restrictions such as prior authorization requirements or BMI thresholds.

Medicare Pilot Program

A new Medicare pilot program, the Medicare GLP-1 Bridge, will offer coverage for certain weight loss drugs starting July 1, 2026, through December 31, 2027. Beneficiaries enrolled in Medicare Part D may pay a flat $50 copay per month for medications such as Wegovy, Zepbound, and Foundayo.

Novo Nordisk Price Reduction Plans

Novo Nordisk announced plans to reduce the monthly list prices of its obesity and diabetes drugs in the U.S. by up to 50%, effective January 1, 2027. Wegovy, its new pill version, Ozempic, and Rybelsus will have a new list price of $675 per month, down from approximately $1,350 per month for Wegovy and $1,027 per month for diabetes drugs.

Eli Lilly's Employer Connect Program

Eli Lilly launched "Employer Connect," a program designed to help employers cover obesity drugs. Through the program, employers can pay a net discounted price of $449 per month for a new multi-dose form of Zepbound across all doses. The platform allows employers to select from 15 third-party program administrators to design benefits.

Cost as a Barrier to Access

The high cost of GLP-1 medications remains a significant barrier to patient access. Approximately one in eight individuals are currently using this class of injectable drugs, with over half reporting difficulties with affordability despite having some insurance coverage. Without insurance coverage, these medications can cost several hundred dollars per month out of pocket.

Financial Forecasts for Major Manufacturers

Novo Nordisk

Novo Nordisk projected a significant decrease in its revenues for the current year, anticipating sales to fall between 5% and 13%. The company cited "unprecedented pricing pressure," including an agreement with the Trump administration to reduce U.S. weight-loss drug prices and the expiration of patent protection for semaglutide in several countries.

Eli Lilly

Eli Lilly forecasted stronger-than-expected sales and profit growth for the current year, projecting 2026 sales between $80 billion and $83 billion, a 45% increase from $65 billion last year, despite U.S. price cuts.